Four years after paying $1.26 billion to bring aboard the gout drug Zurampic (lesinurad), Astrazeneca plc's decision to let Ironwood Pharmaceuticals Inc. pay $100 million for the since-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback